-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written | Edited by Wang Cong | Nagashi Typesetting | Shui Chengwen July 7, 2021, mRNA vaccine giant Moderna, which has gained fame due to the new crown mRNA vaccine, announced that its seasonal influenza mRNA vaccine phase 1/2 clinical trial has completed the first Patient administration
.
This mRNA influenza vaccine, numbered mRNA-1010, is designed to prevent and control common influenza virus strains indicated by the World Health Organization
.
Moderna hopes that this mRNA vaccine can improve the problem of insufficient efficiency of traditional influenza vaccines.
The influenza vaccines currently on the market have an effective rate of only 40% to 60%
.
The phase 1/2 clinical trial of mRNA-1010 will eventually recruit 180 healthy adults to test the safety, patient response and effect of the vaccine
.
At the end of 2020, the US Food and Drug Administration (FDA) approved two mRNA vaccines for the prevention of new coronary pneumonia (COVID-19).
In fact, before the COVID-19 pandemic, mRNA vaccines were attracted by their unique advantages.
A large number of pharmaceutical companies participate in research and development
.
Today, the success of mRNA vaccines in the new crown field has greatly stimulated and promoted the development and expansion of mRNA technology
.
An mRNA vaccine is to directly introduce mRNA encoding a certain viral antigen protein into the animal’s somatic cells, and synthesize the corresponding antigen protein through the host cell’s translation system, thereby inducing the host to produce an immune response to the antigen protein to achieve The purpose of preventing and treating viral infections
.
In recent years, mRNA vaccines have been developing at an alarming rate.
There are not only a variety of SARS-CoV-2 mRNA vaccines, but also mRNA vaccines for rabies, Zika virus and other infectious diseases, cancer, and autoimmune diseases are undergoing clinical trials.
Experiment
.
As the hottest company in the mRNA vaccine field, Moderna has not won the top spot in the mRNA influenza vaccine
.
Just a few days ago, Sanofi and Translate Bio were the first to announce that they have begun a phase 1 clinical trial of an mRNA vaccine against seasonal influenza
.
The mRNA vaccine has many advantages in preventing seasonal influenza.
The current large-scale new crown mRNA application has confirmed the powerful ability and high safety of mRNA.
The rapid response ability of mRNA can achieve a specific immune response within a short time window of seasonal influenza.
And mRNA is suitable for large-scale rapid production and deployment
.
In addition, influenza viruses mutate rapidly, which can easily lead to reduced effects of traditional vaccines, while mRNA vaccines can iterate more quickly to solve this problem
.
Moderna opened the pipeline of three influenza mRNA vaccine research and development in January this year, and formulated a plan to enter the clinic this year
.
Pfizer has also expressed interest in influenza mRNA vaccines, and CureVac, with the support of the Bill and Melinda Gates Foundation, has also begun the research and development of influenza mRNA vaccines
.
Moderna was established in 2010 and is committed to developing innovative therapies based on mRNA technology
.
In December 2018, Moderna went public on the Nasdaq and raised over US$600 million at a price of US$23 per share, setting a new record for biotech companies in IPO fundraising
.
Nowadays, with Moderna's success in the field of mRNA new crown vaccines, its stock price has exceeded US$230 since its listing for more than two years, and its total market value has reached US$94 billion.
It is only a matter of time before it is expected to pass the 100 billion mark
.
In addition to the new crown vaccine, Moderna also has a variety of mRNA vaccines for infectious viruses, as well as more than 20 research projects for cancer vaccines, rare genetic diseases and other diseases.
More than half of them have started clinical trials
.
Today we summarize and introduce Moderna's mRNA R&D pipeline
.
Preventive vaccines Preventive vaccines against infectious diseases are Moderna's core business.
In addition to the mRNA-1273 for the prevention of COVID-19, two other mRNA vaccines against COVID-19 mutant strains are undergoing clinical trials
.
Clinical trials of mRNA vaccines against cytomegalovirus, human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3), Zika virus, respiratory syncytial virus (RSV), and H7N9 influenza virus have begun
.
Preclinical research is under way for mRNA vaccines against Epstein-Barr virus, influenza virus, HIV, and Nipah virus
.
The mRNA-3927 for systemic intracellular treatment of propionic acidemia has begun clinical trials, and mRNA therapies for the treatment of methylmalonic acidemia, phenylketonuria, and glycogen storage disease type 1a are all in the preclinical stage
.
These 4 diseases are rare autosomal recessive inherited diseases.
The correct mRNA is delivered systemically into the cell to express the protein with the correct function and realize the treatment of the disease
.
The local regenerative therapy AZD8601 project is a local mRNA therapy encoding vascular endothelial growth factor (VEGF-A)
.
Developed by Moderna in cooperation with AstraZeneca, it is used to treat heart failure patients who have undergone cardiac bypass graft (CABG) surgery.
Phase 2 clinical trials are currently underway
.
Systemic secretion and cell surface treatments also require systemic delivery treatments.
Among them, mRNA-1944 for chikungunya virus has made the fastest progress.
Phase 1 clinical trials have ended.
After intravenous infusion, it can permanently produce neutralizing genes.
A neutralizing antibody against Kongkenya virus
.
The other three mRNA therapies encoding relaxin, PD-L1 and IL2 are still in the preclinical stage
.
Cancer vaccines These two cancer vaccines were jointly developed with Merke and have entered clinical trials.
They are a personalized cancer vaccine mRNA-4157 and a cancer vaccine mRNA-5671 that targets KRAS mutants
.
The former enhances the effect of immune checkpoint inhibitors by stimulating T cell immune response
.
It can be used in combination with immunoassay inhibitors to improve the effect of cancer treatment
.
The latter encodes the main mutants of KRAS: G12D, G12V, G13D, and G12C, which are used for targeted treatment of non-small cell lung cancer, colorectal cancer, and pancreatic cancer caused by KRAS mutations
.
Intratumor Cancer Immunology In the field of intratumor cancer immunology, Moderna has 3 therapies under development, injecting mRNA encoding pro-inflammatory cytokines into tumors to stimulate inflammation and turn "cold tumors" into "hot tumors.
" , Thereby improving the therapeutic effect of immune checkpoint inhibitors
.
These three therapies are mRNA-2416 encoding OX40L.
The treatment of solid tumors and lymphoma is in clinical phase 1, and the treatment of ovarian cancer is in clinical phase 2
.
MRNA-2752, encoding OX40L+IL23+IL36γ, for the treatment of solid tumors and lymphomas, in clinical phase 1
.
And MED1191, which encodes IL-12, is jointly developed with AstraZeneca to treat solid tumors and is in clinical phase 1
.
Open to reprint this article open to reprint: just leave a message in this article to inform
.
This mRNA influenza vaccine, numbered mRNA-1010, is designed to prevent and control common influenza virus strains indicated by the World Health Organization
.
Moderna hopes that this mRNA vaccine can improve the problem of insufficient efficiency of traditional influenza vaccines.
The influenza vaccines currently on the market have an effective rate of only 40% to 60%
.
The phase 1/2 clinical trial of mRNA-1010 will eventually recruit 180 healthy adults to test the safety, patient response and effect of the vaccine
.
At the end of 2020, the US Food and Drug Administration (FDA) approved two mRNA vaccines for the prevention of new coronary pneumonia (COVID-19).
In fact, before the COVID-19 pandemic, mRNA vaccines were attracted by their unique advantages.
A large number of pharmaceutical companies participate in research and development
.
Today, the success of mRNA vaccines in the new crown field has greatly stimulated and promoted the development and expansion of mRNA technology
.
An mRNA vaccine is to directly introduce mRNA encoding a certain viral antigen protein into the animal’s somatic cells, and synthesize the corresponding antigen protein through the host cell’s translation system, thereby inducing the host to produce an immune response to the antigen protein to achieve The purpose of preventing and treating viral infections
.
In recent years, mRNA vaccines have been developing at an alarming rate.
There are not only a variety of SARS-CoV-2 mRNA vaccines, but also mRNA vaccines for rabies, Zika virus and other infectious diseases, cancer, and autoimmune diseases are undergoing clinical trials.
Experiment
.
As the hottest company in the mRNA vaccine field, Moderna has not won the top spot in the mRNA influenza vaccine
.
Just a few days ago, Sanofi and Translate Bio were the first to announce that they have begun a phase 1 clinical trial of an mRNA vaccine against seasonal influenza
.
The mRNA vaccine has many advantages in preventing seasonal influenza.
The current large-scale new crown mRNA application has confirmed the powerful ability and high safety of mRNA.
The rapid response ability of mRNA can achieve a specific immune response within a short time window of seasonal influenza.
And mRNA is suitable for large-scale rapid production and deployment
.
In addition, influenza viruses mutate rapidly, which can easily lead to reduced effects of traditional vaccines, while mRNA vaccines can iterate more quickly to solve this problem
.
Moderna opened the pipeline of three influenza mRNA vaccine research and development in January this year, and formulated a plan to enter the clinic this year
.
Pfizer has also expressed interest in influenza mRNA vaccines, and CureVac, with the support of the Bill and Melinda Gates Foundation, has also begun the research and development of influenza mRNA vaccines
.
Moderna was established in 2010 and is committed to developing innovative therapies based on mRNA technology
.
In December 2018, Moderna went public on the Nasdaq and raised over US$600 million at a price of US$23 per share, setting a new record for biotech companies in IPO fundraising
.
Nowadays, with Moderna's success in the field of mRNA new crown vaccines, its stock price has exceeded US$230 since its listing for more than two years, and its total market value has reached US$94 billion.
It is only a matter of time before it is expected to pass the 100 billion mark
.
In addition to the new crown vaccine, Moderna also has a variety of mRNA vaccines for infectious viruses, as well as more than 20 research projects for cancer vaccines, rare genetic diseases and other diseases.
More than half of them have started clinical trials
.
Today we summarize and introduce Moderna's mRNA R&D pipeline
.
Preventive vaccines Preventive vaccines against infectious diseases are Moderna's core business.
In addition to the mRNA-1273 for the prevention of COVID-19, two other mRNA vaccines against COVID-19 mutant strains are undergoing clinical trials
.
Clinical trials of mRNA vaccines against cytomegalovirus, human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3), Zika virus, respiratory syncytial virus (RSV), and H7N9 influenza virus have begun
.
Preclinical research is under way for mRNA vaccines against Epstein-Barr virus, influenza virus, HIV, and Nipah virus
.
The mRNA-3927 for systemic intracellular treatment of propionic acidemia has begun clinical trials, and mRNA therapies for the treatment of methylmalonic acidemia, phenylketonuria, and glycogen storage disease type 1a are all in the preclinical stage
.
These 4 diseases are rare autosomal recessive inherited diseases.
The correct mRNA is delivered systemically into the cell to express the protein with the correct function and realize the treatment of the disease
.
The local regenerative therapy AZD8601 project is a local mRNA therapy encoding vascular endothelial growth factor (VEGF-A)
.
Developed by Moderna in cooperation with AstraZeneca, it is used to treat heart failure patients who have undergone cardiac bypass graft (CABG) surgery.
Phase 2 clinical trials are currently underway
.
Systemic secretion and cell surface treatments also require systemic delivery treatments.
Among them, mRNA-1944 for chikungunya virus has made the fastest progress.
Phase 1 clinical trials have ended.
After intravenous infusion, it can permanently produce neutralizing genes.
A neutralizing antibody against Kongkenya virus
.
The other three mRNA therapies encoding relaxin, PD-L1 and IL2 are still in the preclinical stage
.
Cancer vaccines These two cancer vaccines were jointly developed with Merke and have entered clinical trials.
They are a personalized cancer vaccine mRNA-4157 and a cancer vaccine mRNA-5671 that targets KRAS mutants
.
The former enhances the effect of immune checkpoint inhibitors by stimulating T cell immune response
.
It can be used in combination with immunoassay inhibitors to improve the effect of cancer treatment
.
The latter encodes the main mutants of KRAS: G12D, G12V, G13D, and G12C, which are used for targeted treatment of non-small cell lung cancer, colorectal cancer, and pancreatic cancer caused by KRAS mutations
.
Intratumor Cancer Immunology In the field of intratumor cancer immunology, Moderna has 3 therapies under development, injecting mRNA encoding pro-inflammatory cytokines into tumors to stimulate inflammation and turn "cold tumors" into "hot tumors.
" , Thereby improving the therapeutic effect of immune checkpoint inhibitors
.
These three therapies are mRNA-2416 encoding OX40L.
The treatment of solid tumors and lymphoma is in clinical phase 1, and the treatment of ovarian cancer is in clinical phase 2
.
MRNA-2752, encoding OX40L+IL23+IL36γ, for the treatment of solid tumors and lymphomas, in clinical phase 1
.
And MED1191, which encodes IL-12, is jointly developed with AstraZeneca to treat solid tumors and is in clinical phase 1
.
Open to reprint this article open to reprint: just leave a message in this article to inform
